PMS17 Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in kazakhstan
No Thumbnail Available
Date
2014-11-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
A phase III clinical trial demonstrated the advantage of denosumab over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA became available. The purpose of this study was to examine the cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani patients with PC.
Description
Keywords
Citation
C. Bektur, T. Nurgozhin, PMS17 - Cost-Effectiveness of denosumab vs. Brand or generic zoledronic acid in patients with prostate cancer in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Pages A773-A774